Related content

Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate

By Szychowski Jeff M.   Berghella Vincenzo   Owen John   Hankins Gary   Iams Jay D.   Sheffield Jeanne S.   Perez-Delboy Annette   Wing Deborah A.   Guzman Edwin R.  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 25, Iss. 12, 2012-12 ,pp. : 2686-2689

Informa Healthcare

Access to resources Recommend Favorite

Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth

By Calda Pavel  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 22, Iss. 6, 2009-06 ,pp. : 540-542

Informa Healthcare

Access to resources Recommend Favorite

Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice

By Rebarber Andrei   Fox Nathan S.   Klauser Chad K.   Istwan Niki B.   Rhea Debbie J.   Stanziano Gary J.   Saltzman Daniel H.  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 23, Iss. 10, 2010-10 ,pp. : 1139-1142

Informa Healthcare

Access to resources Recommend Favorite

Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy

By Coleman Suzanne   Wallace Lisa   Alexander Jeffrey   Istwan Niki  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 25, Iss. 7, 2012-07 ,pp. : 1034-1038

Informa Healthcare

Access to resources Recommend Favorite

Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate*

By Timofeev Julia   Feghali Maisa   Boyle Annelee   Istwan Niki   Rhea Debbie   Driggers Rita W.  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 26, Iss. 9, 2013-06 ,pp. : 881-884

Informa Healthcare

Access to resources Recommend Favorite